Abstract
Objective To evaluate the efficacy and safety in patients with cirrhotic ascites treated by Wuling Powder. Methods PubMed, Web of science, The Cochrane library, EMbase, CNKI, WAFANG, VIP and SinoMed database were searched. Randomized controlled studies of cirrhotic ascites were collected from the establishment of the database to February 20, 2020. EndNote was used for literature screening, RevMan 5.3 was used for data analysis, GRADEpro was used to evaluate the evidence quality. Results 11 studies with 1054 patients were analyzed, Meta-analysis: @@@2460;Total effective rate: The Wuling powder group was higher (P <0.01)). @@@2461; Liver function: The serum ALT, AST and TBIL in Wuling powder group were significantly lower (P <0.01), the ALB (Albumin) was significantly higher (P <0.05). @@@2462;The incidence of adverse events: There was no significant difference (P = 0.72>0.05). @@@2463; Recurrence rate: The Wuling powder group was lower (P <0.01). @@@2464; GRADE evaluation: The quality of evidence in the total effective rate, ALB index and incidence of adverse reactions was intermediate, the others were low or very low. Conclusions The Wuling powder combined with basic western medical treatment for cirrhotic ascites can significantly improve clinical efficiency, liver function and reduce recurrence rate, the adverse events were not obvious. However, due to the low quality of the included studies, it should be used with caution in the clinic.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call